ALLSCHWIL/BASEL, SWITZERLAND - 17 March 2014 - Actelion Ltd (ATLN.VX) today announced the results of COMPASS-2, a Phase IV, prospective, randomized, double-blind, placebo-controlled, event-driven ...
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results